Perspective Therapeutics

Perspective Therapeutics, Inc. (NYSEAM:CATX) dropped from S&P Biotechnology Select Industry Index.

[212Pb]VMT-α-NET showed favorable safety and anti-tumor activity in a Phase 1/2a trial, with eight of nine patients experiencing durable disease control and six showing tumor volume reduction. Dose escalation is ongoing at 5.0 mCi.

Perspective Therapeutics reported Q3 2024 financial results, with $267.8 million in cash and investments, expected to fund operations into mid-2026. Key developments include advancing [212Pb]VMT01 trials in melanoma patients and [212Pb]VMT-α-NET in neuroendocrine tumors. The company started shipping from a second manufacturing facility in Somerset, New Jersey, and purchased additional facilities in Houston, Chicago, and Los Angeles. Q3 2024 showed a net loss of $15.1 million ($0.21 per share), with research and development expenses at $12.0 million and general administrative expenses at $7.0 million.

Perspective Therapeutics announced Q3 2024 financial results, highlighting progress in clinical programs for melanoma and neuroendocrine tumors, expansion of manufacturing facilities, and sufficient funding through mid-2026.

Perspective Therapeutics, Inc. (NYSEAM:CATX) included in S&P Biotechnology Select Industry Index.

The FDA granted fast track designation to ²¹²Pb VMT01 for treating MC1R-expressing unresectable or metastatic melanoma. VMT01, under investigation in a phase 1/2 study, targets MC1R to deliver ²¹²Pb to tumor sites. The study, recruiting across 9 US locations, aims to assess safety and efficacy, with 52 patients currently enrolled.

Med-tech updates: deals, partnerships, grants, preclinical data, and other briefs involving Aptar, Axogen, Biocare Medical, Boundless Bio, Elutia, Ensigna, Ovation.io, Perspective Therapeutics, PD Theranostics, Sophia Genetics, Venus Medtech, Viz.ai.

Perspective Therapeutics, Inc. is a company focused on innovative therapeutics.

The FDA granted fast track designation to VMT01, a targeted alpha-particle therapy (212Pb) for unresectable or metastatic melanoma patients with MC1R expression. VMT01 targets MC1R-expressing tumors and can be labeled with 203Pb for diagnostic imaging. A phase 1/2a study is ongoing, with plans to open a VMT01/anti–PD-1 combination cohort. The study aims to determine the maximum tolerated dose and evaluate dosimetry using 203Pb-labeled VMT01.